Valdecoxib, >=98% (HPLC)

Valdecoxib, >=98% (HPLC)

Application

Valdecoxib may be used: as cyclooxygenase-2(COX-2) inhibitor in fibroblast cells, as an analyte for mass spectrometry analysis, as an standard in ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) for quantification of valdecoxib in plasma samples

Biochem/physiol Actions

Valdecoxib is a non-steroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) selective inhibitor.

Valdecoxib is reported to elicit anti-inflammatory, analgesic and antipyretic functionality. It acts as a substrate for the liver enzyme cytochrome P450 2C9(CYP2C9) and cytochrome P450 3A4 (CYP3A4).

General description

Valdecoxib (VCX) is a diaryl substituted isoxazole compound. It comprises of sulfonyl propanamide and is a metabolite of parecoxib.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Lipid Signaling research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour InChI key InChI Manufacturer Form Assay Price Quantity
3573585 Valdecoxib, >=98% (HPLC) white to off-white LNPDTQAFDNKSHK-UHFFFAOYSA-N 1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20) SIGMA-ALDRICH powder ≥98% (HPLC)
£671.36 (exc VAT) per 25MG
-
+
3573586 Valdecoxib, >=98% (HPLC) white to off-white LNPDTQAFDNKSHK-UHFFFAOYSA-N 1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20) SIGMA-ALDRICH powder ≥98% (HPLC)
£183.86 (exc VAT) per 5MG
-
+